Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

April 2018; 4 (2) Clinical/Scientific NotesOpen Access

Mutation in the GCH1 gene with dopa-responsive dystonia and phenotypic variability

Elsa Krim, Jerome Aupy, Fabienne Clot, Mickael Bonnan, Pierre Burbaud, Dominique Guehl
First published March 22, 2018, DOI: https://doi.org/10.1212/NXG.0000000000000231
Elsa Krim
From the Centre Hospitalier de Pau (E.K., M.B.), Service de Neurologie; Département de Neurosciences Cliniques (J.A., P.B., D.G.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (J.A., P.B., D.G.), Institut des Maladies Neurodégénératives, CNRS UMR 5293; and AP-HP (F.C.), Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Département de Génétique et Cytogénétique, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome Aupy
From the Centre Hospitalier de Pau (E.K., M.B.), Service de Neurologie; Département de Neurosciences Cliniques (J.A., P.B., D.G.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (J.A., P.B., D.G.), Institut des Maladies Neurodégénératives, CNRS UMR 5293; and AP-HP (F.C.), Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Département de Génétique et Cytogénétique, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabienne Clot
From the Centre Hospitalier de Pau (E.K., M.B.), Service de Neurologie; Département de Neurosciences Cliniques (J.A., P.B., D.G.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (J.A., P.B., D.G.), Institut des Maladies Neurodégénératives, CNRS UMR 5293; and AP-HP (F.C.), Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Département de Génétique et Cytogénétique, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mickael Bonnan
From the Centre Hospitalier de Pau (E.K., M.B.), Service de Neurologie; Département de Neurosciences Cliniques (J.A., P.B., D.G.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (J.A., P.B., D.G.), Institut des Maladies Neurodégénératives, CNRS UMR 5293; and AP-HP (F.C.), Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Département de Génétique et Cytogénétique, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Burbaud
From the Centre Hospitalier de Pau (E.K., M.B.), Service de Neurologie; Département de Neurosciences Cliniques (J.A., P.B., D.G.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (J.A., P.B., D.G.), Institut des Maladies Neurodégénératives, CNRS UMR 5293; and AP-HP (F.C.), Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Département de Génétique et Cytogénétique, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Guehl
From the Centre Hospitalier de Pau (E.K., M.B.), Service de Neurologie; Département de Neurosciences Cliniques (J.A., P.B., D.G.), Centre Hospitalier Universitaire de Bordeaux; Université de Bordeaux (J.A., P.B., D.G.), Institut des Maladies Neurodégénératives, CNRS UMR 5293; and AP-HP (F.C.), Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Département de Génétique et Cytogénétique, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Mutation in the GCH1 gene with dopa-responsive dystonia and phenotypic variability
Elsa Krim, Jerome Aupy, Fabienne Clot, Mickael Bonnan, Pierre Burbaud, Dominique Guehl
Neurol Genet Apr 2018, 4 (2) e231; DOI: 10.1212/NXG.0000000000000231

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
245

Share

  • Article
  • Info & Disclosures
Loading

Dopa-responsive dystonia (DRD) is an autosomal dominant neurologic disorder characterized by incomplete penetrance and high variability of its phenotypic expression.1 The usual phenotype is defined by early-onset isolated dystonia, predominant in the lower limb, with marked diurnal fluctuations and a dramatic and sustained response to low doses of l-DOPA.2 We report 2 members of the same family (mother and daughter) with a nonsense heterozygous mutation (c.706G>T; p.Glu236*) in the GCH1 gene and having DRD with phenotypic variability.

Case (Index case)

A 23-year-old woman presented 10 months ago with severe cervical dystonia. At the age of 19 years, she had transient right lower limb dystonia that appeared immediately after physical effort and lasted 18 months. At the age of 22 years, she presented with left cervical dystonia lasting 2 weeks. Neurologic examination showed severe cervical dystonia with right laterocollis associated with a moderate retrocaput (video segment 1, links.lww.com/NXG/A40). The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS3) score was 49/85, with a severity score of 19/35, a disability score of 24/30 and a pain score of 6/20. Standard biological testing and brain MRI were normal. Levodopa/carbidopa 125 mg per day led to the complete regression of symptoms within 2 months (video segment 2). After 4 months of therapy, she decided to stop her medication. After 30 months of follow-up, her symptoms had not reappeared (video segment 3).

Her mother is 54 years old. At the age of 15 years, she had dystonia in the left foot during exercise, and at the age of 20 years, she had right upper limb dystonia. Diurnal fluctuations and task-specific dystonia appeared progressively over time. Indeed, she has writer's cramp and experiences left lower limb dystonia during prolonged walking. However, she refused to be treated. A molecular study revealed a nonsense mutation in exon 6 of the GCH1 gene (c.706G>T; p.Glu236*) in both of these patients.

Discussion

We report a novel DYT-5a mutation in exon 6 of the GCH1 gene (c.706G>T, p.Glu236*) manifesting as DRD with phenotypic variability, including cervical dystonia. This change is predicted to replace a glutamic acid residue by a stop codon. To date, 214 mutations have been reported in the gene (The Human Gene Mutation Database: hgmd.cf.ac.uk/ac/gene.php?gene=GCH1). A mutation in the GCH1 gene is found in most patients with DRD. It encodes GTP cyclohydrolase 1, an enzyme that catalyzes the first step in the biosynthesis of tetrahydrobiopterin. The latter is an essential cofactor for tyrosine hydroxylase, which is the rate-limiting enzyme for dopamine synthesis.4 As reported in the literature, there is a female-dominant penetration4 but no clear anticipation phenomenon.

The clinical presentations and evolution of our cases were uncommon compared with the phenotypes usually recognized.5 Indeed, our index case initially had severe cervical dystonia, and her mother presented with writer's cramp. However, clinical presentations of DRD can be heterogeneous and encompass a wide variety of symptoms including focal-task dystonia6 and parkinsonism7 or share some clinical similarities with cerebral palsy.8 The time course of symptoms was also very unusual for DRD. Although cervical dystonia quickly and completely abated after levodopa therapy, no relapse occurred after medication withdrawal during the 30 months of follow-up. This is surprising but could potentially be explained by corticostriatal synaptic homeostatic practice-dependent plasticity over time in patients with subtle dopaminergic alterations linked to the GCH1 mutation.9

These 2 patients presented with DRD. Focal dystonia is usually idiopathic with no clear genetic background or relation to basal ganglia lesions.1,10 However, clinicians should be aware of the fact that patients exhibiting focal dystonia can present a GCH1 mutation and dopa responsiveness. This new mutation could potentially explain the unusual phenotype presented by our patients throw further light on the pathophysiology of dystonia.

Author contributions

E.K.: acquisition of data and writing of the first draft of the manuscript. J.A.: writing of the first draft of the manuscript and critical revision of the manuscript for intellectual content. F.C. and M.B.: acquisition of data and critical revision of the manuscript for intellectual content. P.B.: study supervision and critical revision of the manuscript for intellectual content. D.G.: acquisition of data, study concept and design, and critical revision of the manuscript for intellectual content.

Study funding

No targeted funding reported.

Disclosure

The authors report no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Footnotes

  • ↵* These authors contributed equally to the manuscript.

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

  • The Article Processing Charge was funded by the authors.

  • Received October 3, 2017.
  • Accepted in final form January 31, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Albanese A,
    2. Bhatia K,
    3. Bressman SB, et al
    . Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28:863–873.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Maas R,
    2. Wassenberg T,
    3. Lin JP,
    4. van de Warrenburg BPC,
    5. Willemsen M
    . l-Dopa in dystonia: a modern perspective. Neurology 2017;88:1865–1871.
    OpenUrl
  3. 3.↵
    1. Consky ES
    . Clinical assessment of patients with cervical dystonia. In: Therapy Botulinum Toxin. New York: Marcel Dekker; 1994:211–237.
  4. 4.↵
    1. Phukan J,
    2. Albanese A,
    3. Gasser T,
    4. Warner T
    . Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol 2011;10:1074–1085.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Albanese A,
    2. Asmus F,
    3. Bhatia KP, et al
    . EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5–18.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Trender-Gerhard I,
    2. Sweeney MG,
    3. Schwingenschuh P, et al
    . Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009;80:839–845.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Tadic V,
    2. Kasten M,
    3. Bruggemann N,
    4. Stiller S,
    5. Hagenah J,
    6. Klein C
    . Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch Neurol 2012;69:1558–1562.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Nygaard TG,
    2. Waran SP,
    3. Levine RA,
    4. Naini AB,
    5. Chutorian AM
    . Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994;11:236–240.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Quartarone A,
    2. Pisani A
    . Abnormal plasticity in dystonia: disruption of synaptic homeostasis. Neurobiol Dis 2011;42:162–170.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Waddy HM,
    2. Fletcher NA,
    3. Harding AE,
    4. Marsden CD
    . A genetic study of idiopathic focal dystonias. Ann Neurol 1991;29:320–324.
    OpenUrlCrossRefPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case (Index case)
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • All Movement Disorders
  • All Genetics
  • All Clinical Neurology
  • Dystonia

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology Genetics: 7 (1)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise